Company news

ASKA Pharmaceutical Holdings Co., Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

ASKA Pharmaceutical Enters into License Agreement for MHB018A for the Treatment of Thyroid Eye Disease (TED)

November 4, 2026

Supplementary Documents of Consolidated Financial Results for the Second Quarter of FY2026

November 4, 2026

Summary of Financial Results for the First Half (Interim Period) of the Fiscal Year Ending March 31, 2027 (Japanese GAAP) (Consolidated)

November 4, 2026

Completion of Payment for Disposal of Treasury Shares as Restricted Stock Incentives for the Employee Stock Ownership Association and Partial Forfeit

November 2, 2026

Notice Concerning Completion of Payment for Disposal of Treasury Shares as Remuneration for Restricted Shares

August 12, 2026

Summary of Consolidated Financial Results for the First Quarter of FY2026

August 4, 2026

Notice Concerning Disposal of Treasury Shares as Remuneration for Restricted Stock

July 13, 2026

Notice Regarding Results of the 5th Ordinary General Meeting of Shareholders

June 25, 2026

May 31 2024 Licensing Agreement for Relugolix Combination Tablet for Endometriosis in the Gynecologic Disease Area

May 31, 2024

April 25 2024 Personnel Changes of ASKA Pharmaceutical Holdings' Subsidiaries

April 25, 2024

ASKA Pharmaceutical Holdings: March 26 2024 ASKA Pharmaceutical Receives Approval for Partial Change of Manufacturing and Marketing Approval for RIFXIMA® TABLETS for Pediatric Indication

March 26, 2024

ASKA Pharmaceutical Holdings: July 20 2023 ASKA Pharmaceutical Initiates Domestic Phase I II Clinical Trial of Relugolix Combination Tablet (AKP-022)

July 20, 2023

June 27 2023 Personnel Changes of Corporate Officers and Board Members of ASKA Pharmaceutical Holdings Subsidiaries

June 27, 2023

ASKA Pharmaceutical Holdings: June 22 2023 ASKA Pharmaceutical Files an Application for Partial Change of Manufacturing and Marketing Approval for RIFXIMA

June 21, 2023

June 12 2023 NOTICE OF CONVOCATION OF THE 2nd ANNUAL GENERAL MEETING OF SHAREHOLDERS

June 11, 2023

June 12 2023 Matters Subject to Measures for Electronic Provision of the Notice of the 2nd Annual General Meeting of Shareholders

June 11, 2023

June 9 2023 ASKA Pharmaceutical Terminates Joint Research Agreement regarding the Drug Discovery Targeting Specific Ion Channels with RaQualia Pharma

June 9, 2023

ASKA Pharmaceutical Holdings: April 24 2023 ASKA Pharmaceutical Enters into a Comprehensive Business Alliance Agreement on Femtech

April 24, 2023

April 21 2023 ASKA Pharmaceutical Holdings Installs CO₂-Free Electricity and Solar Power Generation Facilities

April 20, 2023

April 7 2023 ASKA Pharmaceutical Terminates Option Agreement with KinoPharma regarding Cervical Dysplasia Treatment

April 6, 2023

March 27 2023 Personnel Change of ASKA Pharmaceutical

March 27, 2023

March 6 2023 Organizational and Personnel Changes of ASKA Pharmaceutical

March 5, 2023

ASKA Pharmaceutical Holdings: February 7 2023 EME and ASKA Announce Collaboration Agreement on Creating Novel PharmaLogical® VHH to address an unmet medical need in Obstetrics and Gynecology

February 7, 2023

August 26 2022 Organizational and Personnel Changes of ASKA Pharmaceutical

August 25, 2022

ASKA Pharmaceutical Holdings: July 19 2022 ASKA Pharmaceutical Signs a Co-promotion Agreement with Melody International for “Fetal Monitor iCTG” in Japan

July 19, 2022

June 28 2022 Personnel Changes of ASKA Pharmaceutical Holdings Subsidiaries

June 27, 2022

Decks

The 5 newest of 7 decks. Every deck is listed under its year.